+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 16Years - 100Years
All Genders
ID00001465

Characterization of Lymphangioleiomyomatosis LAM Pathogenesis and Clinical Progression in Adults Using Advanced Imaging

Led by National Heart, Lung, and Blood Institute (NHLBI) · Updated on 2026-10-29

2000

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Pulmonary lymphangioleiomyomatosis LAM is a severe lung disease that mainly affects women of childbearing age and currently lacks a fully effective treatment. This research aims to understand how LAM develops at the cellular and molecular levels by identifying proteins and genes involved in lung destruction. The study also seeks to define the clinical course of LAM to support the development of better therapies. Participants diagnosed with LAM may be evaluated every six months or as needed for research purposes. The study uses the Toshiba Aquilion ONE CT device, which provides detailed whole-organ imaging with lower radiation exposure, to assist in examining the lungs. Some participants may include those with tuberous sclerosis complex TSC and pulmonary LAM, as well as non-smoking and smoking control groups without lung disease. During the study, participants undergo clinical assessments including imaging and other tests, while pregnant or nursing women are included but certain procedures involving higher risk or radiation are postponed until after pregnancy or nursing. The main outcome is to define the clinical progression and molecular mechanisms of LAM. Participants contribute by attending evaluations at regular intervals, with the goal of advancing knowledge about LAM over time.

CONDITIONS

Brief Title

Study of the Disease Process of Lymphangioleiomyomatosis

Research Team

T

Tatyana A Worthy, R.N.

J

Joel Moss, M.D.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here